We’re reprogramming biology to manufacture life-saving medicines
rBIO’s platform uses synthetic biology to turn microorganisms into miniature drug factories — starting with insulin.
How it works
The heart of rBIO’s platform lies within the past decade of synthetic biology advancements. Recoding microbes allows for the manufacture of high-value proteins and peptides at much higher yields than previous methods.
Unlike legacy biomanufacturing systems, our approach is:
Modular – adaptable to new molecules and hosts
Scalable – suitable for industrial production
High-yield – more than 2x the insulin output of traditional methods
Designed to restore domestic drug manufacturing capacity
A new standard for peptide expression
Our first major success was the development of a synthetic biology-based process to produce biosimilar human insulin. In preclinical validation studies, this product — called R-biolin — has shown:
Consistent performance and purity
Bioequivalence to legacy insulin (Novolin® R)
Reliable production using our proprietary expression system
This is just the beginning. The same platform can be used to manufacture other biologics, including:
Erythropoietin (EPO)
Epinephrine
Discontinued or vulnerable insulin formulations (e.g., Levemir)
Platform highlights
🧬 Custom cellular coding
Our synthetic DNA constructs are purpose-built for high-efficiency expression of complex proteins in microbial systems.
🧪 Optimized microbial hosts
We engineer and fine-tune the cellular environment to enhance protein folding, secretion, and yield.
📈 Double the production output
Our method produces insulin at 2x the yield of traditional recombinant manufacturing methods — a critical economic inflection point.
🏭 Built for scale
rBIO is working with CROs and CDMOs to industrialize production for clinical use and market distribution.
Designed for resilience
The U.S. produces only a small fraction of the essential biologics its population relies on. With major manufacturers exiting older insulin markets, rBIO’s platform provides a path to restore secure, domestic production.
We’re using our proven synthetic biology to close the supply gap — affordably, reliably, and at scale.
Join us
With a home base in Houston, Texas, rBIO is located at a US epicenter of innovation in healthcare and biotechnology.
We are currently engaging with strategic partners, CROs, CDMOs, and early-stage investors.